# Feature Specification: Exploring the Correlation Between Molecular Complexity and Degradation Rates in Pharmaceuticals

**Feature Branch**: `001-molecular-complexity-degradation`  
**Created**: 2023-10-27  
**Status**: Draft  
**Input**: User description: "Explore the correlation between quantitative metrics of molecular complexity (e.g., topological polar surface area, number of rotatable bonds, graph spectral properties) and experimentally-determined degradation rates in FDA-approved small-molecule pharmaceuticals using public datasets (PubChem, DrugBank, ChEMBL) and CPU-tractable statistical analysis."

## User Scenarios & Testing

### User Story 1 - Data Ingestion and Complexity Metric Calculation (Priority: P1)

The system must successfully retrieve a curated set of FDA-approved small-molecule structures and their corresponding experimental degradation data, then compute a standardized set of molecular complexity descriptors for every valid entry.

**Why this priority**: Without a clean, merged dataset containing both structural descriptors and degradation kinetics, no statistical analysis can proceed. This is the foundational data pipeline.

**Independent Test**: The pipeline can be run in isolation to produce a CSV file containing SMILES, calculated metrics (TPSA, rotatable bonds, etc.), and degradation half-lives. The test verifies that the file exists, has no missing values in key columns, and that the calculated metrics match known reference values for a small subset of test molecules.

**Acceptance Scenarios**:

1. **Given** the system has access to public URLs for DrugBank/ChEMBL, **When** the ingestion script executes, **Then** it downloads SMILES strings and degradation half-life data, filters for FDA-approved small molecules, and merges them into a single dataset with no duplicate entries.
2. **Given** a dataset of SMILES strings, **When** the RDKit-based calculator runs, **Then** it successfully computes Topological Polar Surface Area (TPSA), Rotatable Bond Count, Molecular Weight, Aromatic Ring Count, and at least two graph spectral descriptors for every molecule, flagging any calculation failures.
3. **Given** the merged dataset, **When** the validation step runs, **Then** it removes any entries where degradation data is missing or where the molecule structure is invalid, ensuring the final analysis dataset has ≥ 2 degradation measurements per drug.

---

### User Story 2 - Correlation Analysis and Regression Modeling (Priority: P2)

The system must perform exploratory data analysis to identify correlations and fit multiple linear regression models to determine which complexity features independently predict degradation rates. The system MUST standardize all degradation metrics to half-life (hours) before analysis, acknowledging that rate constant (k) and half-life (t1/2) are mathematically inverse.

**Why this priority**: This implements the core scientific hypothesis testing. It transforms the raw data into statistical evidence regarding the research question.

**Independent Test**: The analysis script can be run on the P1 output dataset to generate a correlation matrix and regression coefficients. The test verifies that the output includes p-values, R² scores, and that the models are trained using 5-fold cross-validation.

**Acceptance Scenarios**:

1. **Given** the cleaned dataset of complexity metrics and degradation rates (standardized to half-life), **When** the correlation analysis runs, **Then** it computes Pearson and Spearman correlation matrices and identifies pairs with |r| ≥ 0.5, reporting the p-value for each significant correlation.
2. **Given** the dataset, **When** the multiple linear regression model runs, **Then** it fits a model predicting degradation half-life from complexity features, controlling for known factors (pH, temperature) ONLY if the data has been normalized to standard conditions (25°C, pH 7.4) via the Arrhenius equation; otherwise, these records are excluded from the regression to prevent confounding.
3. **Given** the regression model, **When** the LASSO regression and 5-fold cross-validation run, **Then** it identifies a parsimonious feature set, reports the cross-validated R² score, and ensures the model generalizability is estimated without overfitting.

---

### User Story 3 - Visualization and Reproducibility Reporting (Priority: P3)

The system must generate diagnostic plots and a reproducible report documenting the code, data versions, and results to support the scientific findings.

**Why this priority**: Visualization is required to validate the regression assumptions (residual diagnostics) and to communicate the findings. Reproducibility is a mandatory requirement for the research lifecycle.

**Independent Test**: The script generates a set of PNG/SVG files and a summary report. The test verifies that the plots exist, show the expected regression lines and residual patterns, and that the report includes the exact dataset hashes and code version used.

**Acceptance Scenarios**:

1. **Given** the regression results, **When** the visualization module runs, **Then** it generates scatter plots with regression lines for the top 3 correlated features and residual diagnostic plots to check for homoscedasticity and normality.
2. **Given** the completed analysis, **When** the report generator runs, **Then** it produces a markdown report summarizing the methodology, key correlation coefficients, regression coefficients, and cross-validated R² scores.
3. **Given** the execution environment, **When** the reproducibility check runs, **Then** it logs the exact versions of RDKit, scikit-learn, and the dataset sources (URLs and retrieval dates) to ensure the analysis can be replicated.

### Edge Cases

- What happens when a molecule in the dataset has a non-standard valence or stereochemistry that causes RDKit to fail? (System must flag and exclude, logging the specific SMILES).
- How does the system handle datasets where degradation data is reported in different units (e.g., hours vs. days) or as rate constants (k) vs. half-lives (t1/2)? (System must standardize all degradation metrics to a single unit, e.g., hours, before analysis).
- What happens if the dataset size exceeds the 7 GB RAM limit of the free-tier runner? (System must implement a streaming or chunked processing strategy to fit the data in memory).

## Requirements

### Functional Requirements

- **FR-001**: System MUST retrieve FDA-approved small-molecule structures and experimental degradation data from public sources (PubChem, DrugBank, ChEMBL) and merge them into a unified dataset. (See US-1)
- **FR-002**: System MUST calculate molecular complexity descriptors including Topological Polar Surface Area (TPSA), Rotatable Bond Count, Molecular Weight, Aromatic Ring Count, Wiener index, and Zagreb index using RDKit. (See US-1)
- **FR-003**: System MUST compute Pearson and Spearman correlation coefficients between complexity metrics and degradation rates (standardized to half-life), identifying pairs with |r| ≥ 0.5 and reporting p-values. (See US-2)
- **FR-004**: System MUST fit multiple linear regression and LASSO regression models to identify parsimonious feature sets. If ≥ 50% of records have pH and temperature data, include them as covariates; otherwise, exclude them and log the exclusion reason. (See US-2)
- **FR-005**: System MUST perform 5-fold cross-validation on regression models to estimate generalizability and prevent overfitting, reporting cross-validated R² scores. (See US-2)
- **FR-006**: System MUST generate scatter plots with regression lines and residual diagnostic plots to visualize relationships and validate model assumptions. (See US-3)
- **FR-007**: System MUST document all code versions, dataset sources, and analysis parameters in a reproducible report for public verification. (See US-3)
- **FR-008**: System MUST convert degradation rate constants (k) to half-lives (t1/2) and vice versa to ensure all data is standardized to a single unit (hours) before analysis. (See US-1)
- **FR-009**: System MUST normalize degradation rates to standard conditions (25°C, pH 7.4) using the Arrhenius equation if assay conditions are available. If assay conditions are missing, the system MUST flag the record as 'unnormalized' and exclude it from the primary regression analysis. (See US-2)

### Key Entities

- **Molecule**: Represents a pharmaceutical compound with attributes: SMILES string, Molecular Weight, TPSA, Rotatable Bond Count, Aromatic Ring Count, Graph Spectral Descriptors.
- **DegradationRecord**: Represents experimental stability data with attributes: Drug ID, Half-life (hours), Rate Constant, pH, Temperature, Source Dataset, NormalizationStatus.
- **AnalysisResult**: Represents the output of statistical tests with attributes: Correlation Coefficient, P-value, Regression Coefficient, Cross-Validated R².

## Success Criteria

### Measurable Outcomes

> Planning docs state *what* will be measured and the *source/reference* it is
> measured against; defer specific empirical values (counts, dataset sizes,
> measured quantities, percentages) to the implementation/research phase.

- **SC-001**: The number of successfully merged molecules with valid degradation data is measured against the total number of FDA-approved small molecules listed in DrugBank v2024-01 to determine data coverage. (See US-1)
- **SC-002**: The statistical significance of the relationship (p-value) is measured against the threshold of p < 0.05 to validate the existence of a correlation; the R² score is reported as an outcome metric. (See US-2)
- **SC-003**: The p-value of the strongest correlation between a complexity metric and degradation rate is measured against the significance threshold of p < 0.05 to validate statistical significance. (See US-2)
- **SC-004**: The residual diagnostics are measured against the Shapiro-Wilk test (p > 0.05 for normality) and Breusch-Pagan test (p > 0.05 for homoscedasticity) to validate the appropriateness of the linear regression model. (See US-3)
- **SC-005**: The execution time of the full analysis pipeline is measured against the 6-hour limit of the GitHub Actions free-tier runner to ensure compute feasibility. (See US-3)

## Assumptions

- **Assumption about data availability**: The public datasets (DrugBank, ChEMBL) contain sufficient experimental degradation data (half-lives or rate constants) for a statistically significant subset of FDA-approved small molecules. If the available data is sparse, the analysis will be limited to the available subset, and the sample size/power will be explicitly stated as a limitation.
- **Assumption about variable fit**: The selected public datasets contain the necessary variables (pH, temperature) to control for confounding factors in the regression model. If these are missing for a significant portion of the data, the model will be adjusted to an univariate or bivariate analysis, and the limitation will be documented.
- **Assumption about compute feasibility**: The dataset size (number of molecules) and the complexity of the RDKit calculations will fit within the 7 GB RAM and 14 GB disk constraints of the GitHub Actions free-tier runner. If the dataset is larger, a random sampling strategy will be employed to ensure the analysis completes within the 6-hour time limit.
- **Assumption about methodological framing**: Since the data is observational (no random assignment), all findings regarding the relationship between complexity and degradation will be framed as associational, not causal, in the final report.
- **Assumption about threshold justification**: The threshold of |r| ≥ 0.5 for "moderate-to-strong" correlation is based on standard statistical conventions in the field of chemometrics and will be used as the primary filter for identifying significant relationships. A sensitivity analysis will sweep this threshold over {0.4, 0.5, 0.6} to report how the number of significant correlations varies.
- **Assumption about measurement validity**: The molecular complexity metrics (TPSA, rotatable bonds, etc.) calculated by RDKit are valid proxies for the structural complexity described in the research question, as these are standard, validated descriptors in computational chemistry.
- **Assumption about data heterogeneity**: Public stability data is notoriously heterogeneous. If assay conditions (pH, Temp) are missing for >50% of records, the system will perform a sensitivity analysis on the subset of normalized data and report the limitation. The correlation analysis will be restricted to records that can be normalized or are already at standard conditions to ensure scientific validity.